Estudio multicéntrico del impacto de la implantación de UroLift® en pacientes en tratamiento médico por sintomatología del tracto urinario inferior secundaria a hiperplasia benigna de próstata

IF 1.2 4区医学 Q3 UROLOGY & NEPHROLOGY

Actas urologicas espanolas Pub Date : 2025-05-01 DOI:10.1016/j.acuro.2025.501708

C. González Enguita , L. López Martín , L.M. Herranz Fernández , B. Sinues Ojas , C. Barrera Rodríguez , J. Extramiana Cameno , J. Campá Bortoló , J.M. Oscá García , M. Perán Teruel , V. Gimeno Argente , A. Navarro Beltrán , E. López Alcina , I. Povo Martín , Y.S. Pallás Costa , A. Budía Alba , J. Ortiz Salvador , J.J. Salgado Plonski , P. Suárez Sal , M. Fernández Arjona

{"title":"Estudio multicéntrico del impacto de la implantación de UroLift® en pacientes en tratamiento médico por sintomatología del tracto urinario inferior secundaria a hiperplasia benigna de próstata","authors":"C. González Enguita , L. López Martín , L.M. Herranz Fernández , B. Sinues Ojas , C. Barrera Rodríguez , J. Extramiana Cameno , J. Campá Bortoló , J.M. Oscá García , M. Perán Teruel , V. Gimeno Argente , A. Navarro Beltrán , E. López Alcina , I. Povo Martín , Y.S. Pallás Costa , A. Budía Alba , J. Ortiz Salvador , J.J. Salgado Plonski , P. Suárez Sal , M. Fernández Arjona","doi":"10.1016/j.acuro.2025.501708","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>UroLift® is a minimally invasive treatment for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The primary objective was to evaluate the impact of UroLift® system treatment on quality of life. Secondary objectives assessed the impact on urinary symptoms and sexual function.</div></div><div><h3>Patients and methods</h3><div>Patients at 7 Spanish hospitals undergoing pharmacological treatment were offered the choice to continue this treatment or accept surgical intervention. The primary outcome, impact on quality of life, was assessed using the EuroQol-5D-5L questionnaire. Secondary outcomes, including impact on symptoms, erectile function, and ejaculatory function, were evaluated using the IPSS, SHIM-5, and MSHQ-EjD-SF questionnaires, respectively. Outcomes were compared between groups.</div></div><div><h3>Results</h3><div>91 patients chose UroLift® and 45 continued with pharmacotherapy. At 6months, a positive impact on quality of life was estimated with UroLift® (0.046; SD: 0.02; <em>P</em>      <.001), being significant in subgroups aged >65 (diff.: 1.37), prostate >40cc (diff.: 0.74), PSA>2.2 (diff.: 2.63), and diabetes mellitus (diff.: 1.66), hypertension (diff.: 1.23). Erectile function was not affected (−0.33; SD: 1.99; <em>P</em>  =.019).</div></div><div><h3>Conclusions</h3><div>Minimally invasive UroLift® system treatment is associated with a positive impact on quality of life and urinary symptoms without adversely affecting sexual function.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"49 4","pages":"Article 501708"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480625000269","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives

UroLift® is a minimally invasive treatment for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. The primary objective was to evaluate the impact of UroLift® system treatment on quality of life. Secondary objectives assessed the impact on urinary symptoms and sexual function.

Patients and methods

Patients at 7 Spanish hospitals undergoing pharmacological treatment were offered the choice to continue this treatment or accept surgical intervention. The primary outcome, impact on quality of life, was assessed using the EuroQol-5D-5L questionnaire. Secondary outcomes, including impact on symptoms, erectile function, and ejaculatory function, were evaluated using the IPSS, SHIM-5, and MSHQ-EjD-SF questionnaires, respectively. Outcomes were compared between groups.

Results

91 patients chose UroLift® and 45 continued with pharmacotherapy. At 6 months, a positive impact on quality of life was estimated with UroLift® (0.046; SD: 0.02; P = .067), being significant in subgroups of patients aged > 65 years (diff.: 0.034), PSA > 2.2 (diff.: 0.108), diabetes mellitus (diff.: 0.023), hypertension (diff.: 0.011) or hypercholesterolemia (diff.: 0.016). The impact on symptomatology was superior with UroLift® (−10.07; SD: 1.65; P < .001), being significant in subgroups aged > 65 (diff.: 1.37), prostate > 40 cc (diff.: 0.74), PSA > 2.2 (diff.: 2.63), and diabetes mellitus (diff.: 1.66), hypertension (diff.: 1.23). Erectile function was not affected (−0.33; SD: 1.99; P = .868) while ejaculatory function showed a favourable impact (2.98; SD: 1.26; P = .019).

Conclusions

Minimally invasive UroLift® system treatment is associated with a positive impact on quality of life and urinary symptoms without adversely affecting sexual function.

查看原文本刊更多论文

多中心研究植入UroLift®对继发性下尿路至良性前列腺增生的患者的影响

简介和目的urolift®是一种微创治疗下尿路继发于良性前列腺增生的患者。主要目的是评估UroLift®系统治疗对生活质量的影响。次要目的评估对泌尿系统症状和性功能的影响。患者和方法在西班牙7家医院接受药物治疗的患者可选择继续药物治疗或接受手术干预。使用EuroQol-5D-5L问卷评估主要结局（对生活质量的影响）。次要结局，包括对症状、勃起功能和射精功能的影响，分别使用IPSS、SHIM-5和MSHQ-EjD-SF问卷进行评估。比较两组间的结果。结果91例患者选择了UroLift®，45例患者继续接受药物治疗。在6个月时，UroLift®对生活质量的积极影响(0.046；SD: 0.02;P = .067)，在年龄>；65岁（差异：0.034），PSA >；2.2 （diff. 0.108）、糖尿病（diff. 0.023）、高血压（diff. 0.011）或高胆固醇血症（diff. 0.016）。对症状学的影响优于UroLift®(- 10.07；SD: 1.65;P & lt;.001)，在年龄>；65（差异：1.37），前列腺>；40cc（差值：0.74），PSA >；2.2 (diff. 2.63)，糖尿病（diff. 1.66），高血压（diff. 1.23）。勃起功能未受影响(−0.33；SD: 1.99;P = .868)，而射精功能表现出良好的影响(2.98；SD: 1.26;p = .019)。结论微创UroLift®系统治疗与生活质量和泌尿系统症状的积极影响相关，而不会对性功能产生不利影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

46 days

期刊介绍： Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.